Both retirements were effective immediately.
Following the retirement of Dr. Rouan as chair, the board appointed Alexander L. Cappello and John K. Scott, Jr., who were both existing members of the board, as chair of the board and vice chair of the board, respectively.
Also effective September 14, 2021, the board appointed Cappello to the audit committee, and therefore the current members of the audit committee are Amit Bhalla (chair), Malcolm Witter and Cappello.
On the same date, the board appointed Messrs.
Cappello and Scott to the Compensation, Nominating and Governance Committee and appointed Witter as chair, and therefore, the current members of the CNG Committee are Witter (chair), Scott and Cappello.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
The company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment.
Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.
The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.
Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the company's pipeline through global partnering and commercialization efforts.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer